Volume 5 Supplement 6

International Conference on Prevention & Infection Control (ICPIC 2011)

Open Access

Antimicrobial use prior as a risk factor for developing extended-spectrum beta-lactamse-producing Klebsiella spp. in South Brazil

  • T Ostroski1,
  • C Ito2,
  • C Busato1,
  • MD da Rocha3,
  • C da Silva4,
  • V Bian5 and
  • L Bail2
BMC Proceedings20115(Suppl 6):P138

DOI: 10.1186/1753-6561-5-S6-P138

Published: 29 June 2011

Introduction / objectives

Extended-spectrum beta-lactamase-producing (ESBL) Klebsiella spp. is a problematic nosocomical pathogen around the world. In the present study, we aimed to evaluate the previous use of antibiotics as a risk factor for isolation of ESBL Klebsiella spp.

Methods

In a retrospective case control study between June 2009 and June 2010 at Santa Casa de Misericórdia Hospital, city of Ponta Grossa, south Brazil, 61 Klebsiella spp. (29 ESBL and 32 controls non-ESBL-producing isolates) were enrolled. ESBL were screened by disk diffusion method and double disk approximation method, according to CLSI. Prior use of antibiotic was analyzed in electronic medical records. The antibiotic consumption (DDDs – defined daily doses) was tested using the X2 test (p <0.05).

Results

The DDDs of prior use and full use of cephalosporines, fluoroquinolones, e metronidazole in ESBL and non-ESBL groups were (122.02/145.77; 8.78/69.07), (15.66/22; 0.01/26.2), (47.33/47.66; 3/28) respectively. Prior use of cephalosporines, fluoroquinolones, and metronidazole was higher in ESBL-Klebsiella spp. than non-ESBL-Klebsiella spp. (p<0,001). Carbapenems were not used by the control group.

Conclusion

Theprior use of broad-spectrum cephalosporins, fluoroquinolones and metronidazole is an important risk factor for acquisition of ESBL producing Klebsiella spp.

Disclosure of interest

None declared.

Authors’ Affiliations

(1)
Departamento de Medicina, Universidade Estadual de Ponta Grossa
(2)
Análises Clínicas e Toxicológicas, Universidade Estadual de Ponta Grossa
(3)
Departamento de Saúde Pública, Universidade Estadual de Ponta Grossa
(4)
Intensive Care Unit, Santa Casa de Misericórdia
(5)
Pharmacy, Santa Casa de Misericórdia

Copyright

© Ostroski et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement